Investopedia: Roche, Reloaded

There's a saying that you'll hear used with perennially successful sports franchises – they don't rebuild, they reload. That could apply to Swiss drug giant Roche (OTC:RHHBY) as well, as the company appears to be well on its way with a second generation of top-end oncology drugs, supplemented with promising new drugs in CNS, metabolic disease, and other high-potential treatment areas. While Roche has questions to answer in its diagnostics and life science businesses, as well as its capital priorities, the business looks to be on solid footing for years to come.

Please click the link to read more:
http://www.investopedia.com/stock-analysis/052113/roche-reloaded-rhhby-bmy-gild-mrk-jnj.aspx